NASDAQ · MOVE
Corvex, Inc.
$7.22-$0.09 (-1.23%)
Corvex, Inc.’s quoted price sits in the lower half of its reported 52-week range, 79.29% below the high.
Loading market information…
NASDAQ · BBLG · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Bone Biologics Corporation’s quoted price sits in the lower half of its reported 52-week range, 83.75% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Bone Biologics Corporation’s next earnings report is currently expected on Mar 1, 2027, with estimated earnings per share of -$0.18. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Bone Biologics Corporation’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Bone Biologics Corporation, a medical device enterprise, specializes in fostering bone regeneration for spinal fusion, leveraging its advanced recombinant human protein technology. Its flagship product, NELL-1/DBX, is a unique combination of an osteostimulative recombinant protein designed for precise, targeted control over bone regrowth. The company is currently advancing the NELL-1/DBX Fusion Device, intended for spinal fusion interventions in skeletally mature individuals experiencing single-level degenerative disc disease within the L4-S1 spinal segments. This versatile platform technology also holds the potential to deliver superior outcomes across a wide spectrum of surgical specialties, including spinal, various orthopedic fields, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. Bone Biologics holds a licensing agreement with the UCLA Technology Development Group, which authorizes the development and commercialization of NELL-1 for its spinal fusion applications. The firm was established in 2004 and is based in Burlington, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:56 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 |
|---|
| May 13, 2025 |
| -$0.32+90.12% vs estimate |
| $0.00 |
| Q4 2024 | Mar 5, 2025 | -$0.48+26.15% vs estimate | $0.00 |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$7.22-$0.09 (-1.23%)
Corvex, Inc.’s quoted price sits in the lower half of its reported 52-week range, 79.29% below the high.
$3.61+$0.24 (+7.12%)
HeartSciences Inc.’s quoted price sits in the lower half of its reported 52-week range, 44.2% below the high.
$1.63+$0.03 (+1.61%)
InMed Pharmaceuticals Inc.’s quoted price sits in the upper half of its reported 52-week range, 30.26% below the high.
$4.88+$0.14 (+2.95%)
ENDRA Life Sciences Inc.’s quoted price sits in the lower half of its reported 52-week range, 29.78% below the high.
$1.90+$0.02 (+1.06%)
NanoVibronix, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.83% below the high.
$0.31+$0.01 (+2.64%)
Venus Concept Inc.’s quoted price sits in the lower half of its reported 52-week range, 97.59% below the high.
$1.39-$0.66 (-32.2%)
GlucoTrack, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.33% below the high.
$3.90-$0.24 (-5.8%)
Biodexa Pharmaceuticals Plc’s quoted price sits in the lower half of its reported 52-week range, 98.91% below the high.
